Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

  1. Juan Manuel Carreño
  2. Hala Alshammary
  3. Gagandeep Singh
  4. Ariel Raskin
  5. Fatima Amanat
  6. Angela Amoako
  7. Ana Silvia Gonzalez-Reiche
  8. Adriana van de Guchte
  9. PARIS study group
  10. Komal Srivastava
  11. Emilia Mia Sordillo
  12. D. Noah Sather
  13. Harm van Bakel
  14. Florian Krammer
  15. Viviana Simon

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ebiom.2021.103626
  2. ScreenIT

    SciScore for 10.1101/2021.07.21.21260961: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsField Sample Permit: Nasopharyngeal swab specimens were collected as part of the routine SARS-CoV-2 surveillance conducted by the Mount Sinai Pathogen Surveillance program (IRB approved, HS#13-00981).
    IRB: Briefly, 30 participants enrolled in the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study (reviewed and approved by the Mount Sinai Hospital Institutional Review Board; IRB-20-03374) were invited to provide additional serum samples after receiving their second mRNA vaccine dose.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    After 2-hour incubation, plates were washed three times with PBS-T and 50 μl/well of the pre-diluted secondary antibody anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in goat; Sigma, A0293
    anti-human IgG
    suggested: (Sigma-Aldrich Cat# A0293, RRID:AB_257875)
    Blocking solution was removed and 100 μl/well of mAb 1C7 (anti-SARS nucleoprotein antibody produced in house) diluted in PBS 1% milk (American Bio) at a 1:4000 dilution were added for 1 h at RT.
    anti-SARS nucleoprotein
    suggested: None
    Primary antibody was removed and plates were washed with 200 μl/well of PBS twice, followed by addition of 100 μl/well of goat anti-mouse IgG-HRP (Rockland Immunochemicals) diluted in PBS 1% milk (American Bio) 1:3000.
    anti-mouse IgG-HRP
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Specimens were selected for viral culture on Vero-E6 cells based on the complete viral genome sequence information.
    Vero-E6
    suggested: None
    39 Viruses were grown in Vero.E6 cells for 4-6 days; the supernatant was clarified by centrifugation at 4,000 g for 5 minutes and aliquots were frozen at -80°C for long term use.
    Vero.E6
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
    Vero E6 cells were seeded in 96-well high binding cell culture plates (Thermo Fisher) at a density of 20,000 cells/well in complete Dulbecco’s Modified Eagle Medium (cDMEM).
    Vero E6
    suggested: None
    Software and Algorithms
    SentencesResources
    Phylogeny of SARS-CoV-2 lineages: The phylogenetic relationships of the SARS-CoV-2 isolates from the Pathogen Surveillance Program of the Mount Sinai Health System are depicted in a New York focused background from GISAID.
    Pathogen Surveillance Program
    suggested: None
    Area under the curve (AUC) values were calculated and plotted using GraphPad Prism 7.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    A non linear regression curve fit analysis, using Prism 9 software (GraphPad), was performed to calculate the inhibitory dilution 50% (ID50), using top and bottom constraints of 100% and 0% respectively.
    Prism
    suggested: (PRISM, RRID:SCR_005375)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.07.21.21260961 on medRxiv